The effect of UIC2 anti-pgp antibody and IgG2a control antibody on apoptotic cell death in pgp+ve leukemic samples
| Patient . | 7-AAD High (Nonviable) with IgG2a, % . | 7-AAD High (Nonviable) with UIC2, % . | Change, % . |
|---|---|---|---|
| GO | 23.3 | 25.8 | 11 |
| JD | 7.3 | 11.5 | 57 |
| RF | 27.2 | 53 | 95 |
| DS | 27.6 | 48 | 74 |
| BB | 30.8 | 45.2 | 47 |
| Patient . | 7-AAD High (Nonviable) with IgG2a, % . | 7-AAD High (Nonviable) with UIC2, % . | Change, % . |
|---|---|---|---|
| GO | 23.3 | 25.8 | 11 |
| JD | 7.3 | 11.5 | 57 |
| RF | 27.2 | 53 | 95 |
| DS | 27.6 | 48 | 74 |
| BB | 30.8 | 45.2 | 47 |
In samples from patients DS and BB, which had comparatively low D values for pgp expression (see Table 1), viability was decreased after 18 hours with 10 μg/mL UIC2. In the 3 remaining samples, there was little or no effect at this dose and time, and results obtained using 25 μg/mL UIC2 and control IgG2a for 28 hours are given.